FP05-3 Implication of Progranulin and C1q/TNF-related Protein-3 (CTRP3) on Inflammation and Atherosclerosis in Subjects With or Without Metabolic Syndrome

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: FP05-Lipids: Regulation & Mechanism of Disease
Saturday, June 15, 2013: 11:00 AM-11:30 AM
Presentation Start Time: 11:10 AM
Room 133 (Moscone Center)

Poster Board SAT-736
Ho Cheol Hong*1, Hae Yoon Choi1, Jae Hee Ahn1, Nam Hoon Kim1, Yoon Jung Kim1, Hye-Jin Yoo2, Hee Young Kim3, Ji A Seo4, Sin Gon Kim5, Nan Hee Kim6, Kyoung-Mook Choi7, Sei Hyun Baik1 and Dong Seop Choi8
1College of Medicine, Korea University, Seoul, Korea, 2Korea University Guro Hospital, Seoul, South Korea, 3Korea Univ ANAM Hospital, Seoul, South Korea, 4Korea Univ Ansan Hosp, Ansan City, South Korea, 5Korea Univ Anam Hosp, Seoul, South Korea, 6Korea Univ Ansan Hosp, Ansan, South Korea, 7Korea Guro Univ Hosp, Seoul, South Korea, 8Korea UNIV HOSP, Seoul, South Korea
Objective: Progranulin and C1q/TNF-related protein-3 (CTRP3) were recently discovered as novel adipokines which may link obesity with altered regulation of glucose metabolism, chronic inflammation and insulin resistance.
Research Design and Methods: We examined circulating progranulin and CTRP3 concentrations in 127 subjects with (n = 44) or without metabolic syndrome (n = 83). Furthermore, we evaluated the relationship of progranulin and CTRP3 levels with inflammatory markers and cardiometabolic risk factors, including high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), estimated glomerular filtration rate (eGFR), and adiponectin serum concentrations, as well as carotid intima-media thickness (CIMT).
Results: Circulating progranulin levels are significantly related with inflammatory markers, hsCRP (r = 0.30, P = 0.001) and IL-6 (r = 0.30, P = 0.001), whereas CTRP3 concentrations exhibit a significant association with cardiometabolic risk factors, including waist circumference (r = -0.21), diastolic blood pressure (r = -0.21), fasting glucose (r = -0.20), triglyceride (r = -0.34), total cholesterol (r = -0.25), eGFR (r = 0.39) and adiponectin (r = 0.26) levels. Serum progranulin concentrations were higher in patients with metabolic syndrome than those of the control group (199.55 [179.33, 215.53] vs. 185.10 [160.30, 204.90], P = 0.051) and the number of metabolic syndrome components had a significant positive correlation with progranulin levels (r = 0.227, P =0.010). In multiple regression analysis, IL-6 and triglyceride levels were significant predictors of serum progranulin levels (R2 = 0.251). Furthermore, serum progranulin level was an independent predictor for increased CIMT in subjects without metabolic syndrome after adjusting for other cardiovascular risk factors (R2 = 0.365).
Conclusions: Serum progranulin levels are significantly associated with systemic inflammatory markers and were an independent predictor for atherosclerosis in subjects without metabolic syndrome.

Nothing to Disclose: HCH, HYC, JHA, NHK, YJK, HJY, HYK, JAS, SGK, NHK, KMC, SHB, DSC

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm